12Jan
Sanofi to Acquire Kymab for up to $1.45 Billion
Sanofi announced that it has entered into an agreement to acquire Kymab, a clinical-stage biopharmaceutical company developing fully human monoclonal antibodies with a focus on immune-mediated diseases and immuno-oncology therapeutics, for an upfront payment of approximately $1.1 billion and up to $350 million upon achievement of certain milestones. The acquisition will give Sanofi full global rights to Kymab’s KY1005, which binds to OX40-Ligand and has the potential to treat a wide variety of...
By:
Goodwin
Related
The National Labor Relations Board earlier today held that a courier services company misclassified ...
Read More >
The FAA has begun the process of amending its regulations to require that flight attendants at U.S. ...
Read More >
In today’s edition of Sunday Book Review we pay tribute to Roger Kahn with a review of the followin...
Read More >
Seyfarth Synopsis: OSHA reminds employers of the hazards of distracted driving. OSHA has recently ...
Read More >
Our Antitrust and M&A Groups offer practical advice for companies seeking mergers or acquisitions in...
Read More >
USCIS Announces Implementation of Its H-1B Electronic Registration Tool - After several months of ...
Read More >